Is Harmony Biosciences (HRMY) a Solid Growth Stock? 3 Reasons to Think "Yes"

Core Viewpoint - Investors are increasingly seeking growth stocks that demonstrate above-average growth potential, with Harmony Biosciences Holdings, Inc. (HRMY) identified as a strong candidate due to its favorable growth metrics and Zacks Rank [2][10]. Group 1: Earnings Growth - Harmony Biosciences has a historical EPS growth rate of 13.1%, but projected EPS growth for this year is significantly higher at 26.7%, surpassing the industry average of 13% [4]. - Double-digit earnings growth is a key indicator for growth investors, suggesting strong future prospects and potential stock price increases [3]. Group 2: Cash Flow Growth - The company currently exhibits a year-over-year cash flow growth of 10%, which is notably higher than the industry average of -4.5% [5]. - Over the past 3-5 years, Harmony Biosciences has achieved an annualized cash flow growth rate of 25.7%, compared to the industry average of 4.1% [6]. Group 3: Earnings Estimate Revisions - Recent upward revisions in current-year earnings estimates for Harmony Biosciences indicate a positive trend, with the Zacks Consensus Estimate increasing by 7.5% over the past month [8]. - The correlation between earnings estimate revisions and stock price movements supports the potential for near-term price appreciation [7]. Group 4: Overall Assessment - Harmony Biosciences has achieved a Zacks Rank of 1 (Strong Buy) and a Growth Score of B, indicating its potential as an outperformer and a solid choice for growth investors [10].